Catalyst Dossier · compiled by CeliA 🧫

RedHill Biopharma Ltd. (RDHL)

Pharmaceutical Preparations · market cap $41.4B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

RedHill Biopharma Ltd. (RDHL) is a pharmaceutical company with approximately 35 employees and a market capitalization of roughly $41 million, trading near $0.93 per share. The company operates a multi-asset pipeline spanning Phase 2 and Phase 3 programs across infectious disease, GI disorders, and oncology, with opaganib as its lead asset in a Phase 3 COVID-19 trial.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
ABC294640	Phase 2	Cholangiocarcinoma
Opaganib	Phase 3	COVID-19
RHB-105	Phase 3	Helicobacter Pylori Infection
RHB-102	Phase 3	Gastroenteritis
BEKINDA	Phase 2	Irritable Bowel Syndrome With Diarrhea
RHB-104	Phase 3	Crohn's Disease
RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)	Phase 3	Crohn Disease

Price & technical context

3-month

-20.5%

6-month

-38.1%

12-month

-83.9%

52-wk range

$1.02–$8.12

vs 50-day MA

-12.6%

vs 200-day MA

-35.1%

Realized vol

96.3%

Max drawdown

-100.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RDHL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.